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Abstract: The Blm10/PA200 family of proteasome activators modulates the peptidase activity of the
core particle (20S CP). They participate in opening the 20S CP gate, thus facilitating the degradation
of unstructured proteins such as tau and Dnm1 in a ubiquitin- and ATP-independent manner.
Furthermore, PA200 also participates in the degradation of acetylated histones. In our study, we use
a combination of yeast and human cell systems to investigate the role of Blm10/PA200 in the
degradation of N-terminal Huntingtin fragments (N-Htt). We demonstrate that the human PA200
binds to N-Htt. The loss of Blm10 in yeast or PA200 in human cells results in increased mutant
N-Htt aggregate formation and elevated cellular toxicity. Furthermore, Blm10 in vitro accelerates the
proteasomal degradation of soluble N-Htt. Collectively, our data suggest N-Htt as a new substrate
for Blm10/PA200-proteasomes and point to new approaches in Huntington’s disease (HD) research.
Keywords: Huntington’s disease; huntingtin protein (Htt), Blm10/PA200-proteasomes; degradation;
soluble N-Htt; mutant N-Htt aggregates

1. Introduction
The fundamental cause of many neurodegenerative diseases is the formation of misfolded
oligomers and aggregates, which eventually leads to cytotoxicity and cellular death [1]. Most of
the time, misfolded proteins and aggregates are successfully removed from cells by the two major
proteolytic pathways, the ubiquitin-proteasome machinery (UPS) and autophagy [1–4]. However,
in certain neurodegenerative diseases, such as Parkinson’s or Huntington’s disease, the genetic
mutations, which are present in specific proteins (α-synuclein and huntingtin protein, respectively)
can lead to the formation of larger oligomers and aggregates [5–7]. These aberrant proteins are quite
resistant to degradation pathways.
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Huntington’s disease is caused by a CAG repeat expansion mutation in exon 1 of the huntingtin
gene (HTT). Thus, the mutant huntingtin protein (mHtt) contains a polyglutamine tract (polyQ) in
the N-terminal region [8]. The severity and the age of onset of the disease greatly depend on the
number of polyQ repeats [9]. Mutant Htt is ubiquitously expressed but mainly targets the central
nervous system, damaging and killing medium spiny neurons [10,11]. Furthermore, although mHtt
does not form insoluble oligomers and aggregates in peripheral tissues, the mutant protein perturbs
the homeostasis of peripheral tissues, including elevated reactive oxygen species (ROS) production and
mitochondrial dysfunction [12]. The clinical manifestation of Huntington’s disease is characterized
by motor dysfunction, severe psychiatric problems, including aggression, depression, and suicidal
tendencies, and a decline in cognitive functions. Quality control of the cellular proteome is maintained
even in HD. However, with aging and disease progression, the cellular proteostasis network becomes
impaired and dysfunctional leading to cellular death [6].
The regulation of the proteasome (26S) is defined by the topology of its proteolytic core complex,
the core particle (20S CP proteasome) [13–16]. Degradation of substrate proteins takes place inside
the proteolytic chamber of the core particle. The 20S CP is composed of seven α-subunits and seven
β-subunits arranged to form four heptameric rings. Three of the seven β-subunits, the β1 -, β2 -,
and the β5 -subunits, have proteolytic activities. The proteolytic activity of the proteasome includes
caspase-like, trypsin-like, and chymotrypsin-like activities. The UPS can degrade mHtt protein and
has been implicated in the pathogenesis of HD [17–21]. Both in vitro and in vivo studies demonstrate
that the proteasome inefficiently degrades the long polyglutamine containing proteins, including the
N-terminal fragments of mHtt [22], leading to detrimental cellular effects. Hipp et al. suggested
that the activity of the proteasome is indirectly inhibited by aggregated mHtt fragments due to
their exceeded solubility threshold [23]. According to their results, N-terminal fragments of mutant
Htt, composed of the first 17 amino acids of the huntingtin protein and the adjacent polyQ stretch,
are neither competitive nor noncompetitive inhibitors of 26S and they do not choke the proteasome.
They propose that the accumulation of ubiquitin conjugates in cells is the consequence of limited 26S
capacity, which originates from the disrupted protein folding homeostasis caused by mHtt aggregates.
To promote substrate degradation, the core particle of the proteasome interacts with proteasome
activators at either one or both ends of the 20S CP to activate the proteasome, which in turn opens
the gate and allows specific substrate entry into the core. In addition to the well-characterized 19S
regulatory particle (RP/19S/PA700), which is required for ATP- and ubiquitin-dependent substrate
unfolding and degradation, alternative activators of the proteasomes have been described. Activators of
the PA28 protein family are present in higher eukaryotes [24,25], while the conserved Blm10/PA200
family is present in yeast and mammals, respectively [26–28]. Both Blm10 and PA200 mediate ATPand ubiquitin-independent specific substrate degradation such as unstructured proteins and acetylated
histones [29–32].
Recently, cryo-EM studies revealed that PA200 binding induces gate opening of the 20S CP [33,34].
PA200 binding initiates rearrangements of the central pore regions of the α ring of the 20S CP into
an open channel conformation and helps small substrate peptides pass through rather than globular
proteins. PA200 binds to active 20S CP and forms both singly capped and doubly capped variants
in vitro.
In the present study, we found that PA200 colocalizes and binds to wild-type (wt) and mutant N-Htt.
Furthermore, our data establish that the Blm10/PA200 family enhances the proteasomal degradation
of nonaggregated, soluble N-Htt in vitro compared to 20S CP. We also demonstrate that loss of
Blm10/PA200 leads to bigger aggregates of mutant Htt in size and number, and causes elevated cellular
toxicity. In summary, our results add a new substrate to the palette of Blm10/PA200-proteasomes
substrates. Enhancing the activity of the proteasome may help cells to overcome the toxicity of
expanded Htt polyQ, and might represent a new therapeutic approach to fight HD.
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2. Materials and Methods
Reagents and materials were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise stated.
2.1. Cell Lines and Cell Culture
The human neuroblastoma SH-SY5Y cell line (European Tissue Culture) was cultured in Dulbecco’s
Modified Eagle’s Medium-high glucose (DMEM), supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (Gibco/ThermoFisher, Waltham, MA, USA), 2 mM l-glutamine, 1 mM sodium pyruvate
solution, and 100 IU/mL penicillin-100 µg/mL streptomycin (Pen-Strep), incubated at 37 ◦ C and 5% CO2 .
The stably depleted cell line for PA200 (shPA200) and the corresponding control with empty vector
(pGIPZ-GFP) were maintained under 1.25 µg/mL puromycin selection as previously described [35].
2.2. Yeast Strains, Media, and Growth Conditions
Yeast strains were obtained using standard genetic techniques. All strains are isogenic to BY4741
or BY4742 [36] and are S288C derived. Complete gene deletion, promoter exchange, or tag integration
were constructed at the genomic locus by homologous recombination using standard techniques [37,38].
Primer sequences are available upon request. Unless otherwise noted, strains were grown at 30 ◦ C in
yeast peptone dextrose (YPD) and were harvested at OD660nm ≈ 1 for log phase cells, at OD660nm ≈ 12
for postdiauxic shift (PDS) phase cells, and after 5 days for stat phase cells. Yeast strains used in this
study are provided in Table 1.
Table 1. Strains used in this study.
Strains

Genotypes

Ref.

BY4742

MATα his3∆1 leu2∆0 lys2∆0 ura3∆0
MATa his3 ∆1 leu2∆0 met15∆0 ura3∆0 PRE1tev ProA (HIS3)
(KanMX)GAL1pHA3BLM10
MATα his3∆1 leu2∆0 met15∆0 ura3∆0 blm10∆::NatMX
MATα his3∆1 leu2∆0 met15∆0 lys2∆0 ura3∆0
MATα his3∆1 leu2∆0 ura3∆0 rpn4∆::KanMX
MATa his3∆1 leu2∆0 met15∆0 ura3∆0 PRE1TEV ProA(HIS3)
MATa his3∆1 leu2∆0 met15∆0 ura3∆0+ pYES2-Htt25Q-CFP
MATa his3 ∆1 leu2∆0 lys2∆0 ura3∆0 rpn4∆::HphMX+ pYES2-Htt25Q-CFP
MATa his3∆1 leu2∆0 met15∆0 ura3∆0+ pYES2-Htt103Q-CFP
MATa his3∆1 leu2∆0 lys2∆0 ura3∆0 rpn4∆::HphMX+
pYES2-Htt103Q-CFP
MATa MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 blm10∆::NatMX+
pYES2-Htt25Q-CFP
MATa MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 blm10∆::NatMX+
pYES2-Htt103Q-CFP

[36]

yMS122
yMS131
yMS268
yMS285
yMS476
yMS1371
yMS1372
yMS1377
yMS1378
yMS1392
yMS1393

[27]
[39]
[39]
[31]
[29]
[40]
This study
[40]
This study
This study
This study

2.3. Yeast Phenotype Analysis
To perform a phenotype analysis of cells expressing N-Htt fragments with either 25 (Htt25Q) or
103 glutamines (Htt103Q), cells were grown overnight in synthetic complete media containing 2% (v/v)
raffinose and lacking the amino acid for plasmid selection. Induction was initiated by the addition of
2% (v/v) galactose. After 18 h of induction, cells were diluted to OD660nm = 0.4 and spotted onto solid
synthetic drop-out media containing either 2% (v/v) glucose or 2% (v/v) galactose. Colony growth on
the plates was monitored daily.
2.4. Plasmids Constructs
The pHM6-Q23 and pHM6-Q74 plasmids were gifts from David Rubinsztein (Addgene plasmid
# 40263; http://n2t.net/addgene: 40263; RRID: Addgene_40263, and Addgene plasmid # 40264;
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http://n2t.net/addgene: 40264; RRID: Addgene_40264) (Addgene, Watertown, MA, USA) [41].
The pGEX-5 plasmids expressing the GST–N-huntingtin protein fusion constructs containing either
18 polyQ (control) or 51 polyQ (toxic) were obtained from Dr. Ron Kopito, Stanford University, CA.
These constructs were modified by the addition of a TEV protease cleavage site between the GST and
huntingtin protein exon 1 coding regions. The presence of the GST tag maintains both the control and
the toxic variants in a soluble form. Upon cleavage of the GST moiety with TEV protease, the protein
with 51 polyQ stretches rapidly forms high molecular weight aggregates [23,42]. Control pGEX-4T-2
was a gift from Dr. Anita Boratkó. The pYES2-25Q-CFP or pYES2-103Q-CFP, expressing huntingtin
exon1 fragments with 25 or 103 glutamines (25Q or mutant 103Q) fused to GFP under the control of
the GAL1 promoter were kindly provided by Michael Sherman [43].
2.5. Immunofluorescence and Image Analysis
For immunofluorescence staining, neuroblastoma cells were cultured on glass coverslips coated
with 1% gelatin. The next day, cells were transiently transfected with the pHM6-Q23 to express the wt
huntingtin fragments or pHM6-Q74 to express the mutant huntingtin fragments using Lipofectamine
3000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol.
After 48 h transfection, cells were rinsed with 1 X PBS, fixed in 4% paraformaldehyde for 15 min at
room temperature (RT), permeabilized with 0.1% Triton X-100 in PBS for 30 min, and blocked with
blocking buffer (3% BSA, PBS, and 0.01% Triton X-100) for 1 h. Cells were incubated for 1.5 h at RT
with primary antibodies (listed in Table 2) in blocking buffer. Cells were then rinsed three times with
PBS with 0.01% Triton X-100 and then incubated for 1.5 h at RT with secondary antibodies (listed in
Table 2) in 1% BSA, PBS, and 0.01% Triton X-100. The nuclei were counterstained with 1 µg/mL DAPI.
Coverslips were mounted on slides with mounting media (Dabco 33-LV: Mowiol 4-88, 1:50). Images
were taken with an SP8 confocal laser scanning microscope (Leica Biosystems, Wetzlar, Germany)
using a 63X HC PL Apo oil CS2 objective. Post-acquisition images were adjusted using LAS X v 3.7.1
software (Leica Biosystems, Wetzlar, Germany). Confocal images were analyzed for aggregate number
and size by ImageJ software (imagej.nih.gov). A total of 1000 cells with aggregates from each cell line
were counted and analyzed.
Pearson’s and Manders’ coefficients were evaluated using the JACoP plugin in ImageJ [44].
The r values are Pearson’s cross-correlation coefficients indicating colocalization of N-Htt and PA200.
Manders (M1, M2) are overlap coefficients. M1 determines the fraction of N-Htt overlapping PA200
and M2 determines the fraction of PA200 overlapping N-Htt. We measured M1 and M2 above threshold
values to remove the noise and background in the images and optimize M1 and M2 measurements.
Visualization of N-Htt fragments in live yeast cells was achieved by monitoring GFP fluorescence
in cells carrying the plasmids pYES25Q-GFP or pYES103Q-GFP. Live-yeast cell fluorescence was
monitored using a fluorescence microscope Olympus BX61 (Olympus Corporation, Tokyo, Japan) at
the Albert Einstein Imaging Facility with a 60X or 100X NA 1.4 objective (PlanApo). Fluorescence or
differential interference contrast (DIC) images were captured with a cooled CCD camera (Sensicam
QE, Cooke, MI, USA) using IPlab 4.0 software (BD Biosciences, San Jose, CA, USA). Images were
identically processed using ImageJ software 1.42q. For excitation of Htt25Q-GFP and Htt103Q-GFP,
a 425–445 nm band pass filter was used. Emitted light was detected with a 476 nm long pass filter
(filter set Olympus) (Olympus Corporation, Tokyo, Japan).
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Table 2. List of primary and secondary antibodies used in this study.
Primary Antibody (Source)
Anti-HA-Tag (Cell Signaling Technology, Danvers, MA, USA)

Catalog No.

Host

Dilution

Rabbit

1:1000

Method
Immunoblot

3724S

Anti-HA-Tag (Cell Signaling Technology, Danvers, MA, USA)

2367

Mouse

PSME4/PA200 (Novus Biologicals, Littleton, CO, USA)

NBP2-22236

Rabbit

Anti-GFP (Clontech, Mountain View, CA, USA)

632592

Anti-GST Tag (Upstate Biotechnology, Lake Placid, NY, USA)
β1 subunit of Proteasome 20S (human) (Enzo Biochem,
Farmingdale, NY, USA).

Immunofluorescence

1:1000

Immunoblot

1:500

Immunofluorescence

1:2000

Immunoblot

1:1000

Immunofluorescence

Rabbit

1:1000

Immunoblot

05-311

Mouse

1:1000

Immunoblot

BML-PW8140-0100

Mouse

1:1000

Immunoblot

Proteasome 20S (Yeast) core subunits (Enzo Biochem,
Farmingdale, NY, USA)

BML-PW9355-0100 Rabbite

1:1000

Immunoblot

Actin (Santa Cruz Biotechnology, Dallas, TX, USA)

Sc-1616

Goat

1:10,000

Immunoblot

Host

Dilution

Method

1:1000

Immunofluorescence

1:1000

Immunofluorescence

Secondary Antibody (Source)

Catalog No.
A11005

Mouse

A31631

Rabbit

A11001

Mouse

A11034

Rabbit

IRDye 800CW (LI-COR, Lincoln, NE, USA)

926-32211

Rabbit

1:10,000

Immunoblot

IRDye 680RD (LI-COR, Lincoln, NE, USA)

926-68072

Mouse

1:5000

Immunoblot

Anti-Mouse IgG Antibody, HRP conjugate

A9044

Rabbit

1:3000

Immunoblot

Anti-Goat IgG Antibody, HRP conjugate

A8919

Rabbit

1:3000

Immunoblot

Anti-Rabbit IgG Antibody, HRP conjugate

A0545

Goat

1:3000

Immunoblot

Alexa fluor 594 (Thermo Fisher Scientific, Waltham, MA, USA)

Alexa fluor 488 (Thermo Fisher Scientific, Waltham, MA, USA)

2.6. Bacterial Expression and GST Pull-Down Assay
Escherichia coli BL21 (DE3) cells transformed with pGEX-4T-2, huntingtin Q18 encoding pGEX-5,
or huntingtin Q51 encoding pGEX-5 constructs were induced with 1 mM IPTG and grown at
room temperature (RT) with shaking for 3 h at 180 rpm. Cells were harvested by centrifugation
and sonicated in lysis buffer (50 mM Tris–HCl (pH 7.5), 0.1% Tween 20, 0.2% 2-mercaptoethanol,
protease inhibitors). GST-tagged proteins were isolated by affinity chromatography on glutathione
Sepharose 4B (GE Healthcare Life Sciences, Chicago, IL, USA) according to the manufacturer’s protocol.
SH-SY5Y grown in 100-mm plates were washed with 1X ice-cold PBS, scraped, and lysed in 600 µL
lysis buffer. The lysates were incubated with GST or GST-fused huntingtin Q18 and Q51 proteins
coupled to glutathione Sepharose beads for 16 h at 4 ◦ C using gentle rotation. The beads were washed
three times with 1X TBST then GST fused proteins were eluted by boiling the samples in 2X SDS
sample buffer and tested for interacting proteins by Western blot.
2.7. Filter Trap Assay from Human Neuroblastoma Cells
The filter trap assay was performed to analyze SDS-insoluble aggregates according to the published
literature [45,46]. After 48 h of transient transfection with pHM6-HA-Q23 and pHM6-HA-Q74,
cells were rinsed with 1X PBS and lysed with lysis buffer (40 mM HEPES, pH 7.5, 50 mM KCl, 1% (v/v)
Triton X-100, 2 mM DTT, 5 mM EDTA) supplemented with 1X cOmplete™, Mini, EDTA-free protease
inhibitor cocktail. Cell lysates were fractionated into supernatant (S) and pellet (P) fractions by
centrifugation (20 min, 16,000 rpm at 4 ◦ C). Pellets with aggregates were resuspended in 75 µL DNA
digestion buffer (40 mM Tris-HCl, pH 8.0, 6 mM MgCl2 , 10 mM NaCl, 10 mM CaCl2 ), and incubated
for 1 h at 37 ◦ C with 30 U DNase I (Zymo Research, Irvine, CA, USA) and 100 µg/mL RNase. Reactions
were interrupted by 2X termination buffer (4% SDS, 40 mM EDTA, 100 mM DTT). Samples (10 µg,
S and P) were adjusted up to 200 µL by adding filter trap buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl
(TBS) with 2% SDS). Each sample was filtered through a 0.2 µm nitrocellulose membrane (Bio-Rad
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Laboratories, Hercules, CA, USA) which was pre-equilibrated in filter trap buffer using a Minifold I
96-well dot-blot system (Whatman GmbH, Dassel, Germany). The dot-blots were washed twice with
filter trap wash buffer (TBS with 0.1% SDS). The membrane was removed and blocked for 1 h at RT
with Odyssey® blocking buffer (LI-COR, Lincoln, NE, USA), and probed with primary antibody in
Odyssey® blocking buffer with 0.1% Tween overnight at 4 ◦ C. Membranes were washed three times for
5 min in TBS with 0.05% Tween then probed with Infrared-labeled (IRDye® 800 CW, IRDye® 680 RD)
secondary antibodies in Odyssey® blocking buffer with 0.1% Tween for 1.5 h at RT. After secondary
labeling, membranes were washed three times for 5 min in TBS with 0.05% Tween. The dot-blots
were scanned using LI-COR ODYSSEY® CLx infrared imaging system (LI-COR, Lincoln, NE, USA).
The images and infrared signals were analyzed using Image Studio software v 5.2 (LI-COR, Lincoln,
NE, USA).
2.8. Filter Retardation Assay and Gradient Gel Analysis from Yeast Cells
The preparation of samples for protein aggregation studies was performed as described previously
by Ocampo and Barrientos [47]. Briefly, wt or blm10∆ cells carrying pYES25Q-GFP or pYES103Q-GFP
were grown overnight in synthetic complete media containing 2% (v/v) raffinose and lacking the
amino acid for plasmid selection. For induction, galactose was added at a final concentration of
2% (v/v) to induce protein expression for 10, 14, and 18 h. The cells were pelleted by centrifugation
at 1500× g for 10 min and then washed with 1.2 M sorbitol. Cells were resuspended in a cell wall
digestion buffer (1.2 M sorbitol, 20 mM K3 PO4 , pH 7.4, and 0.6 mg/mL zymolase-100T) and incubated
for 30–60 min at 30 ◦ C with gentle shaking. After ≈80% of the cells were converted to spheroplasts,
they were diluted by the addition of 1.2 M sorbitol with 20 mM KPO4 (pH 7.5) and pelleted by
centrifugation at 5500× g for 10 min followed by washing two additional times (1.2 M sorbitol, 20 mM
KPO4, pH 7.5). The spheroplasts were resuspended in lysis buffer (40 mM Hepes, pH 7.5, 50 mM
KCl, 1% (v/v) Triton X-100, 2 mM DTT, 5 mM EDTA, and 1 mM PMSF) and incubated on ice for 1 h.
The upper layer (T, total) was carefully transferred to new tubes and spun down for 10 min at 2000× g.
After centrifugation, the supernatant (S, supernatant) and the pellet (P, pellet) fractions were separated.
The pellet fraction was washed with lysis buffer and resuspended in an appropriate volume of water.
Protein concentration was determined for each fraction (T, S, P) with a Bradford protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). To quantify the amount of SDS-insoluble protein aggregates a filter
retardation assay was performed following the method described by Alberti et al. (2010) with minor
modifications [48]. The protein (2, 5, 7, and 10 µg) was solubilized in 200 µL of TBS containing with
0.1% SDS and filtered through a 0.2 µm pore size of cellulose acetate membrane (Whatman GmbH,
Dassel, Germany) using a Whatman Vacuum Minifold I System apparatus (Whatman GmbH, Dassel,
Germany). Each well was washed twice with TBS. The membrane was blocked with 1X TBS + 0.05%
(v/v) Tween 20 containing 5% (v/v) dry milk and the retained SDS insoluble aggregates were detected
with a polyclonal anti-GFP. The detection of signals was performed with ImageQuant LAS4000 mini
system (GE Healthcare Life Sciences, Chicago, IL, USA).
For gradient gel analysis, samples were loaded onto a NuPAGE 3–8% Tris-Acetate gel according to
the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). The stacking and separating
gels were kept and proteins were transferred to a cellulose acetate membrane (Whatman GmbH, Dassel,
Germany). The membrane was blocked with 1X TBS + 0.05% (v/v) Tween 20 containing 5% (v/v) dry
milk and the retained SDS insoluble aggregates were detected by a polyclonal anti-GFP antibody.
The detection of signals was performed with ImageQuant LAS4000 mini system (GE Healthcare Life
Sciences, Chicago, IL, USA).
2.9. RNA Extraction and cDNA Reverse Transcription
Total RNA was extracted using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA)
following the manufacturer’s protocol. Samples were treated with DNase I for 15 min at RT in DNA
digestion buffer before the reverse transcription (Zymo Research, Irvine, CA, USA). To perform cDNA
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synthesis, a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA)
was used to reverse transcribe 1 µg total RNA with random primers.
2.10. Quantitative Real-Time PCR
Real-time PCR was performed with a Lightcycler 480 thermocycler (Roche Molecular Systems,
Basel, Switzerland) using SYBR Green Lo-ROX qPCR master mix (Xceed, IAB, Strašnice, Czech Republic).
Cycling conditions were as follows: Stage 1: Preincubation 95 ◦ C 10 min, 1 cycle; Stage 2: Amplification
95 ◦ C 15 s, 60 ◦ C 30 s, for 40 cycles; Stage 3: Melt curve analysis 95 ◦ C 0.05 s, 65 ◦ C 1 min, 97 ◦ C
0 s, 1 cycle; Stage 4: Cooling 40 ◦ C 30 s 1 cycle. Threshold values (Ct -values) for all replicates were
normalized to GAPDH. Each of the biological replicates contained three technical replicates for each
gene in each sample. To compare the effect of PA200 depletion, 2−∆∆Ct values were calculated to obtain
fold expression levels. The primer list is provided in Table 3.
Table 3. Primers used in RT-qPCR reactions.
Gene

Forward Primer

Reverse Primer
50 -GTAGGTCAGCACACTTCCTATTC-30
50 -GATCTCGCTCCTGGAAGATG-30

PMSE4(PA200)

Human

50 -ATGGAGAGTGCCTGAACTATTG-30

GAPDH

Human

50 -GAGTCAACGGATTTGGTCGT-30

2.11. SDS-PAGE and Western Blot
Cells were washed on ice with PBS and lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 0.5% Na-deoxycholate, 2 mM EDTA, 1% NP-40, and 50 mM NaF) with protease inhibitors
containing 1 mM benzamidine, 1 mM PMSF, and cOmplete Mini-EDTA-free protease inhibitors (Merck
KGaA, Darmstadt, Germany). Cells were homogenized by sonication (three times, 1 s with 15 s breaks
on ice) and cell lysates were cleared by centrifugation (10 min, 16,000 rpm at 4 ◦ C). Protein (30 µg)
was mixed with Laemmli buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol
blue, and freshly added 140 mM DTT) and boiled (5 min at 95 ◦ C). Each sample was separated by
SDS-PAGE, transferred onto 0.45 µm nitrocellulose membranes (GE Healthcare Life Sciences, Chicago,
IL, USA). Blots were immunodetected with antibodies listed in Table 2. Bands signals were enhanced
using a chemiluminescent substrate (Santa Cruz Biotechnology, Dallas, TX, USA) and captured by
ChemiDoc Imager (Bio-Rad Laboratories, Hercules, CA, USA). Densitometry was performed using
Image Lab.v.6.0.1 software (Bio-Rad Laboratories, Hercules, CA, USA).
2.12. Purification of Proteasome Complexes
Proteasome core particle (CP), Blm10-CP, and 26S complexes were purified as described
previously [27,29]. Cells from yMS476 for the CP purification were grown in 2% glucose medium until
O.D. 4–5. Cells from yMS122 for the Blm10-CP and 26S purification were grown first in 2% glucose
medium until O.D. 2 and switched to 2% galactose medium for 8 h induction until O.D. 4–5. The cell
powder was thawed in one pellet volume of 50 mM Tris, pH 8.0, 50 mM NaCl, 5 mM MgCl, and 1 mM
DTT. The same buffer, but supplemented with 10% glycerol, 5 mM ATP, and 1X ATP-regenerating
mix (ARS) was used for 26S purification. The thawed cell lysate was centrifuged in a GSA rotor
(Sorvall, Newtown, CT) for 30 min at 13,000 rpm, and the pellet was discarded. The cleared lysate
was batch-incubated with IgG affinity gel (Cappel) for 1.5 h at 4 ◦ C, and the beads were collected and
washed with a solution of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl, and 0.5 mM DTT. Proteasome
complexes were eluted after cleavage with tobacco etch viral protease (Invitrogen) and concentrated in
a Vivaspin 6 Centrifugal Concentrator of 100 kDa proteins (GE Healthcare). Then, the concentrated
proteasome complexes were injected into a Superose 6 10/300 GL column. The complexes were first
resolved on 3.5% acrylamide native gels, followed by SDS-PAGE and Coomassie blue staining to assess
complex composition and purity of the sample. The same protocol was used to produce doubly and
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singly capped Blm10-CP. The doubly capped complex comes out earlier when a size-exclusion column
was used during purification.
2.13. Proteasome (20S CP) Activity Assay
Proteasome (20S CP) activity was measured based on the hydrolysis of the fluorogenic substrate
Suc-LLVY-AMC (Enzo) for chymotrypsin-like peptidase activity and was performed according to
published protocols [29,49].
2.14. In Vitro Protein Degradation Assay
The in vitro degradation assay was performed according to Tar et al. [31]. GST-HttQ18 or
GST-Htt51 turnover was tested at 30 ◦ C in a reaction mixture containing 50 mM Tris pH 7.5, 25 mM
NaCl, 2.5 mM MgCl2 , 0.5 mM EDTA, 1 mM DTT, 40 nM HttQ51 or HttQ18, and 12 nM Blm10-CP or
12 nM CP or 12 nM 26S in a final volume of 15 µL for each time point. The reactions were incubated at
30 ◦ C and reactions were terminated at the indicated time points by the addition of 4X sample buffer
followed by boiling for 3 min and by immunoblot analysis with an anti-GST antibody (Upstate) for
N-Htt Q18 or N-Htt Q51 degradation. Proteasome levels in the reactions were monitored with an anti
20S antibody (BioMol). The protein signals were visualized by ImageQuant LAS 4000 and the intensities
of protein bands were quantified using the ImageQuant software (GE Healthcare Life Sciences, Chicago,
IL, USA). GST-N-HttQ18 and GST-N-HttQ51 were purified as described previously [50].
2.15. Peptidomics Analysis
Peptides were cleaned up using a stage-tip micro column [51] and resuspended in water with
0.1% formic acid (Merck, Darmstadt, Germany). The samples were measured on a Q-Exactive
mass spectrometer (Thermo-Fisher, Waltham, MA, USA) coupled to a Proxeon nano-LC system
(Thermo-Fisher, Waltham, MA, USA) in data-dependent acquisition mode, selecting the top 10 peaks
for HCD fragmentation. A 3-h gradient (solvent A: 5% acetonitrile, 0.1% formic acid; solvent B: 80%
acetonitrile, 0.1% formic acid) was applied for the samples using an in-house prepared nano-LC
column (0.075 mm × 250 mm, 3 µm Reprosil C18 , Dr. Maisch GmbH, Germany). A volume of 5 µL
sample was injected and the peptides eluted with 3 h gradients of 4–76% ACN and 0.1% formic acid
in water at flow rates of 0.25 µL/min. MS acquisition was performed at a resolution of 70,000 in the
scan range from 300 to 1700 m/z. Dynamic exclusion was set to 30 s and the normalized collision
energy to 26 eV. The mass window for precursor ion selection was set to 2.0 m/z. Data were analyzed
using the MaxQuant software. The internal Andromeda search engine was used to search MS2 spectra
against the Saccharomyces cerevisiae proteome database and the Htt-18Q and Htt51Q sequences of
the recombinant Htt proteins containing forward and reverse sequences. The search included the
variable modification of methionine oxidation and fixed modification of carbamidomethyl cysteine.
The minimal peptide length was set to seven amino acids, with an unspecific digest pattern. The FDR
was set to 0.01 for peptide and protein identifications. The data was further analyzed using the R
software (www.r-project.org) and the tidyverse analysis package [52].
2.16. Statistical Analysis
All quantified data are presented as mean ± standard deviation (SD) of n ≥ 3 experiments.
Statistical analysis was performed using unpaired Student’s t-test to compare the variance between
two data sets only and ANOVA followed by Tukey multiple comparisons test when comparing the
variances between more than two data sets. All statistical measurements were performed using
GraphPad Prism 8.2.1 software. p < 0.05 was considered significant (* indicates p < 0.05, ** indicates
p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001).
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3. Results
3.1. Blm10-Proteasomes Antagonize the Toxicity of Mutant Huntingtin Expression in Yeast
HD is an age-related disorder where cells expressing polyQ expansions do not show severe toxicity
until the patient reaches 40 years of age [9,53]. Similarly, yeast cells do not display immediate cell
death upon polyQ expression. However, the expression of mutant huntingtin in yeast causes severe
growth deficits. Therefore, yeast can be used as an excellent cytotoxicity model for neurodegenerative
diseases [47,54,55]. First, we examined whether the loss of BLM10 affects the viability of yeast
cells expressing Htt103Q, an exon1 fragment of huntingtin containing a stretch of 103 glutamines.
We induced the expression of the Htt103Q and determined yeast viability by a serial dilution
assay. The absence of BLM10 caused increased cell lethality (Figure 1A, upper right panel) after
induction of the expression of Htt103Q compared to wt or the RPN4 deletion strain (rpn4∆). Rpn4 is
a proteasome related transcription factor. It acts as a transcriptional activator of several genes
encoding proteasomal subunits [39]. The expression of Rpn4 is regulated by the 26S proteasome
providing a negative feedback-loop through proteasomal degradation. According to a previous study,
the loss of BLM10 results in a mitochondrial respiratory deficit, increased mitochondrial oxidative
stress, and hypersensitivity to death stimuli, while rpn4∆ cells did not show the same phenotype.
Reduced proteasome activity by the deletion of RPN4 primarily affects mitochondrial fusion. However,
loss of BLM10 increases mitochondrial fission indicating the specificity of Blm10 towards specific
substrates [31]. Phenotypic analyses also demonstrate that manipulating the level of Rpn4 influences
the replicative lifespan of yeast. Rpn4 stabilization leading to elevated proteasome capacity enhances
the viability of cells against proteolytic stress, but does not influence cell response against oxidative
stress [40]. In addition, a recent study demonstrated that the loss of PA200/Blm10 is the leading cause
of the decline in proteasome activity during aging, which strengthens the idea that PA200/Blm10 might
have a major role in age-related diseases. Furthermore, the deletion of RPN4 decreases the level of
Blm10 suggesting that Rpn4 partially promotes the transcription of Blm10 [56].
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Figure 1. Cellular toxicity and aggregation of toxic N-terminal Htt fragments (N-Htt) in wild type (wt)
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The viability of cells expressing the nontoxic huntingtin fragment composed of 25 glutamines was
unaffected by the absence of BLM10 (Figure 1A, lower panels). Next, we tested whether blm10∆ (BLM10
deletion) cells would exhibit altered aggregation of the toxic Htt fragment via a filter retardation
assay after 10, 14, and 18 h of induction. In both wild type (wt) and blm10∆ cells, accumulation of
the aggregates increased in a time-dependent manner (Figure 1B). We performed statistical analysis
of samples of 10 µg protein and normalized the values to wt cells. We observed a slight increase of
chemiluminescent intensity in total lysate and the aggregates containing pellet after 18 h galactose
Biomolecules 2020, 10, x
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moderately (<0.7) and strongly (>0.7) positive correlation between the two proteins [58,59]. MCC was
also calculated using JaCoP. MCC is very sensitive to noise; therefore, to calculate M1 and M2, we set
Biomolecules
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of 32
a threshold
to10,the
estimated background. M1 (or M2) shows the proportion of the green 15
signal
concurrent with the signal in the red channel over its total intensities. M1 indicates the fraction of NHttQs-HA-tag overlapping PA200, and M2 indicates the fraction of PA200 overlapping N-HttQs-HAand strongly (>0.7) positive correlation between the two proteins [58,59]. MCC was also calculated
tag. The M1 value of N-HttQ23-HA and PA200 is 0.35, which means that the two pixels overlap by
using JaCoP. MCC is very sensitive to noise; therefore, to calculate M1 and M2, we set a threshold
35%. The M2 value of PA200-N-HttQ23-HA is 0.34, which means that the two pixels overlap by 34%.
to the estimated background. M1 (or M2) shows the proportion of the green signal concurrent with
(Figure 3B). For N-HttQ74-HA-PA200 (M1) and PA200- N-HttQ74-HA (M2), the two pixels overlap
the signal in the red channel over its total intensities. M1 indicates the fraction of N-HttQs-HA-tag
by 30% and 44.8%, respectively (Figure 3D) [57,60].
overlapping PA200, and M2 indicates the fraction of PA200 overlapping N-HttQs-HA-tag. The M1
We previously established an SH-SY5Y cell-line to stably deplete PMSE4 (PA200) using shRNA
value of N-HttQ23-HA and PA200 is 0.35, which means that the two pixels overlap by 35%. The M2
lentiviral technology (shPA200 cells) [35]. We validated again the knockdown efficiency by qRT-PCR
value of PA200-N-HttQ23-HA is 0.34, which means that the two pixels overlap by 34%. (Figure 3B).
and Western blotting (Supplementary Figure S2A,B). To confirm the specificity of the PA200
For N-HttQ74-HA-PA200 (M1) and PA200- N-HttQ74-HA (M2), the two pixels overlap by 30% and
antibody, we tested the antibody in the shPA200 cells and corresponding controls. As Supplementary
44.8%, respectively (Figure 3D) [57,60].
Figure S2C shows, the antibody is specific to PA200 and is suitable for immunofluorescent studies.
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3.3. PA200 Interacts with wt and Mutant N-Htt In Vitro
PA200, and the M2 value between PA200-N-Htt74Q-HA-tag.
To determine if PA200 interacts with the N-Htt-fragments, pull-down assays were performed to
check
the ability
of the recombinant
GST-Htt18Q
and to
GST-Htt51Q
to bind endogenous
PA200 from
previously
established
an SH-SY5Y
cell-line
stably deplete
PMSE4 (PA200)
using

We
shRNA
lentiviral technology (shPA200 cells) [35]. We validated again the knockdown efficiency by qRT-PCR
and Western blotting (Supplementary Figure S2A,B). To confirm the specificity of the PA200 antibody,
we tested the antibody in the shPA200 cells and corresponding controls. As Supplementary Figure S2C
shows, the antibody is specific to PA200 and is suitable for immunofluorescent studies.
3.3. PA200 Interacts with wt and Mutant N-Htt In Vitro
To determine if PA200 interacts with the N-Htt-fragments, pull-down assays were performed
to check the ability of the recombinant GST-Htt18Q and GST-Htt51Q to bind endogenous PA200
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from human neuroblastoma cell lysates. Plasmids expressing the GST–N-huntingtin protein fusion
constructs contained either 18 polyQ (control) or 51 polyQ (toxic). These constructs were modified by
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Figure 4. PA200 binds to wt and mutant N-Htt in vitro. (A) Bacterially expressed glutathione
S-transferase (GST), GST-Htt18Q, and GST-Htt51Q were loaded onto glutathione sepharose and
purified. The efficiency of protein purification was visualized by Coomassie Blue staining. (B,C) GST,
GST-Htt18Q, and GSTHtt51Q recombinant proteins were immobilized on GSH–Sepharose 4B and
incubated with SH-SY5Y neuroblastoma cell lysate. Eluted proteins were analyzed with antibodies
specific for PA200 (B) and β1 subunit of 20S CP (C) by Western blotting.

Figure 4. PA200 binds to wt and mutant N-Htt in vitro. (A) Bacterially expressed glutathione Stransferase (GST), GST-Htt18Q, and GST-Htt51Q were loaded onto glutathione sepharose and
purified. The efficiency of protein purification was visualized by Coomassie Blue staining. (B,C) GST,
GST-Htt18Q, and GSTHtt51Q recombinant proteins were immobilized on GSH–Sepharose 4B and
incubated with SH-SY5Y neuroblastoma cell lysate. Eluted proteins were analyzed with antibodies
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specific for PA200 (B) and β1 subunit of 20S CP (C) by Western blotting.
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Figure 5. PA200 depletion leads to increased mutant N-Htt fragments aggregate size and number.
(A,B) Representative confocal microscopy images of wt and mutant N-Htt fragments in control and
PA200-depleted neuroblastoma human cells are shown. White squares represent the corresponding insets
(lower panels); arrows indicate the toxic Htt aggregates. Control and shPA200 cells were transfected with
pHM6-Q23 (with HA-tag) and pHM6-Q74 (with HA-tag) constructs for 48 h. The cells were immunolabeled
with HA-tag antibody followed by Alexa Fluor 594 secondary antibody (Red). (C,D) Aggregate size and
number were determined from the confocal microscopy images using ImageJ software (imagej.nih.gov).
The data are presented as mean ± SD obtained from 1057 control cells and 1207 shPA200 cells from five
independent experiments. Statistical analysis was carried out using unpaired Student’s t-test with GraphPad
Prism v. 8.2.1 software (* indicates p < 0.05; ** indicates p < 0.01). (E) Representative images of filter
trap immunoblots of SDS-resistant aggregates and PA200 protein. After 48 h transient transfection with
pHM6-Q23 (HA-tag) or pHM6-Q74 (HA-tag), control and shPA200 cells were lysed with filter trap lysis buffer.
Equal supernatant (S) and pellet (P) protein amounts (10 µg) from control and shPA200 cells were loaded
onto 0.2 µm nitrocellulose membrane then probed with HA-tag and PA200 antibodies. Antigen–antibody
complexes were detected using infrared fluorescent dye (IRDye 700 Red for HA-tag and IRDye 800 Green
for PA200) secondary antibodies. Dot blots were visualized with the LI-COR Odyssey infrared imaging
system. (F) Quantification of SDS-resistant aggregates detected by filter trap assays of control and shPA200
cells is shown. Data are shown as mean ± SD of four independent experiments. Statistical analysis was
accomplished by ANOVA test using GraphPad Prism v. 8.2.1 software (*** indicates p < 0.001; **** indicates
p < 0.0001).
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We performed filter trap assays to analyze SDS-insoluble aggregates of the overexpressed N-Htt
protein fragments and to confirm our confocal microscopy analysis. After 48 h transfection with vectors
containing the wt or mutant N-terminal huntingtin, cell lysates were fractionated into supernatant
(S) and pellet fraction with aggregates (P) by centrifugation. We detected a significantly higher
level of SDS-insoluble aggregates of mutant huntingtin in the pellet fraction of shPA200 cells as
demonstrated in Figure 5E,F. Moreover, when stained with the anti-PA200 antibody, we detected PA200
in the aggregate-containing pellet fraction of control cells, suggesting that PA200 is recruited to the
mHtt-induced aggregates.
3.5. Blm10/PA200 Contribute to the Degradation of wt and Mutant N-Htt In Vitro
We hypothesized that Blm10/PA200 might be involved in the proteasomal degradation of wt and
mutant N-Htt. Thus, we performed an in vitro assay to investigate whether Blm10-CP complexes
can promote the degradation of wt huntingtin with 18Q and mutant huntingtin with 51Q glutamine
stretches. For this assay, equal molar amounts of purified CP or Blm10-CP were incubated with the wt
and mutant huntingtin fragments. Both CP and Blm10-CP complexes promoted the degradation of wt
and mutant huntingtin fragments (Figure 6). Moreover, our data demonstrate that wt huntingtin with
18 (Figure 6B) and mutant huntingtin with 51 polyQ stretches (Figure 6A) are rapidly and significantly
degraded by the proteasome in vitro in the presence of the yeast ortholog of PA200. Furthermore,
we show that the wt and mutant N-Htt remain stable in the absence of the catalytically active
proteasome (Figure 6C) and that the protein GST is not degraded by the proteasome (Supplementary
Figure S5) indicating the specificity of CP and Blm10-CP toward N-Htt. We also demonstrate that
Blm10 alone does not degrade the wt or the mutant N-Htt (Supplementary Figure S5). To show that
Blm10 is specifically involved in the degradation of the non-ubiquitinated, soluble N-Htt Q51, we also
performed the degradation assay with purified 26S. Figure 6D demonstrates that the mutant N-Htt
remain stable over time in the presence of 26S. We conclude that binding of the PA200 yeast ortholog
Blm10 activates the proteolytic activity of the CP, resulting in a more efficient turnover of soluble,
nonaggregated huntingtin fragments.
To confirm the purity of complexes and determine if the purified CP and Blm10-CP complexes are
catalytically active, we studied the purified complexes by Coomassie stain (Figure 6F left panel) and
performed a native gel analysis followed by an in-gel activity assay and native gel protein stain as
previously published [27,29]. CP samples were affinity purified and then subjected to size-exclusion
chromatography. Blm10 degradation products are labeled with asterisk [27]. As shown in the right
upper panel of Figure 6E, both purified proteasome complexes, the CP and the CP capped by Blm10,
are fully active.

Biomolecules 2020, 10, 1581
Biomolecules 2020, 10, x

21 of 32
21 of 32

Figure 6. Cont.

Biomolecules 2020, 10, 1581
Biomolecules 2020, 10, x

22 of 32
22 of 32

Figure 6. The degradation
of soluble
GST-Htt51Q
GST-Htt18Q
is accelerated
Blm10 in vitro.
Figure 6. The degradation
of soluble
GST-Htt51Qand
and GST-Htt18Q
is accelerated
by Blm10 in by
vitro.
(A,B)
Uncleaved
GST-Htt51Q
and
GST-Htt18Q
were
incubated
with
equal
molar
amounts
of
purified
(A,B) Uncleaved GST-Htt51Q and GST-Htt18Q were incubated with equal molar amounts of purified
CP or Blm10-CP. (Left panels) Aliquots were taken at the times indicated and separated by SDSCP or Blm10-CP. PAGE.
(Left Htt51Q
panels)
were
taken
at the timeswith
indicated
andantibody.
separated
andAliquots
Htt18Q were
detected
by immunoblotting
a GST-specific
(Rightby SDS-PAGE.
panels)
Quantification
of degradation
of soluble GST-Htt51Q
GST-Htt18Q by the
proteasome.(Right panels)
Htt51Q and Htt18Q
were
detected
by immunoblotting
with and
a GST-specific
antibody.
Data are shown as mean ± SD of three independent experiments. Statistical analysis was accomplished
Quantification of degradation of soluble GST-Htt51Q and GST-Htt18Q by the proteasome. Data are
by ANOVA test using GraphPad Prism v. 8.2.1 software (* indicates p < 0.05; ** indicates p < 0.01; ****
shown as mean indicates
± SD of
experiments.
analysis
was
accomplished by
p <three
0.0001),independent
* indicates statistical
comparison of CPStatistical
complexes with
Q18 or Q51
to N-Htt
# indicates statistical comparison between CP complexes (CP and
samples
without
CP
complexes,
ANOVA test using GraphPad Prism
v. 8.2.1 software (* indicates p < 0.05; ** indicates p < 0.01;
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N-Htt samples without CP complexes, # indicates statistical comparison between CP complexes (CP
and Blm10-CP) with Q18 or Q51. ### indicates p < 0.001; #### indicates p < 0.0001, ns indicates not
significant). (C) GST-Htt51Q and GST-Htt18Q are not degraded and remain stable in the absence of
CP. Uncleaved, soluble GST-Htt51Q and GST-Htt18Q were incubated in the absence of purified CP.
Aliquots were taken at the times indicated and separated by SDS-PAGE. Htt51Q and Htt18Q were
detected by immunoblotting with a GST-specific antibody. (D) GST-Htt51Q is not degraded by the
26S proteasome and remains stable. Uncleaved, soluble GST-Htt51Q were incubated in the presence
of purified 26S. Aliquots were taken at the times indicated and separated by SDS-PAGE. Htt51Q was
detected by immunoblotting with a GST-specific antibody. (E) (left panel) Equal molar amounts of
Blm10-CP or CP were separated by SDS-PAGE and stained with Coomassie stain to demonstrate that
equal amounts of CP were present in the assay. (Right panels) Blm10 degradation products are marked
with an asterisk. Proteasomal complex composition (CP, Blm10-CP doubly and singly capped) was
assessed by native gel electrophoresis followed by an in-gel activity assay and a native gel protein stain.
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3.6. Blm10 Enhances the Ability of the Proteasome to Cut within Expanded polyQ Repeats
Previously it was published that Blm10 stimulates the trypsin-like and caspase-like protease
activities, however the chymotrypsin-like activity is unaffected [29]. Thus, we set out to monitor the
proteolytic processing of the recombinant GST-Htt18Q and GST-Htt51Q by mass spectrometry-based
peptidomics. Recombinant, purified GST-Htt18Q and GST-Htt51Q were treated with purified CP and
Blm10-CP and subjected to mass spectrometric analysis. Of the 2417 detected peptides 461 peptides
were derived from the recombinant Htt constructs (Figure 7B). The peptide analysis reveals that
without CP, one peptide is detectable, which originates from the Q51 and none from the Q18 Htt’s
poly Q-stretch. The CP’s addition to the reaction generates a significant number of peptides from the
poly-Q stretch of Q18 and Q51 Htt (second column of the heat map Figure 7A). The addition of BLM10
to the reaction generates additional peptides (e.g., SLKSFQQ) and enhances the production of other
peptides also found in the CP alone reaction (e.g., KASFESLKSFQQ), as visible by an enhanced peptide
intensity (third column of the heat map Figure 7A. Double cuts in the polyQ stretch are not enhanced
as seen in the Q51 heat map for the poly-Q only peptides.
The addition of Blm10 to the CP leads to an increased degradation activity (Figure 7C), while the
overall length distribution is not significantly changed (Figure 7D).
Next, we probed our peptide data for specific digestion patterns. Therefore, we analyzed first
the differences between the identified peptides from the in vitro degradation assays. The peptides
generated by the CP have a large overlap (71%) with the peptides produced by the CP-Blm10 complex
(Figure 8A). The amounts of the peptides were significantly higher in the CP-Blm10 experiment
(Figure 8B) indicating a higher throughput of the CP-Blm10 complex compared to the CP alone. To look
deeper into changes in the amino acid sequences of the generated peptides, we analyzed the peptide
sequences upstream of the cleavage sites of the identified peptides. To describe cleavage specificity,
we used the Berger and Schechter nomenclature [61]. Proteolytic cleavage depends on substrate
recognition by the protease [62,63]. According to Berger and Schechter, substrate residues around
the protease-binding pocket are denoted as P4-P3-P2-P1↓P10 -P20 -P30 -P40 . The arrow indicates that
the cleavage occurs between residues P1 and P10 (Figure 8C). The analysis of the sequences using
sequence logos (Figure 8D) and by positional enrichment of the amino acids (Figure 8E), shows the
amino acid preference of the CP. The cleavage specificity of the proteasome is not significantly changed
in the presence of Blm10 in the degradation assays of N-Htt fragments. The proteasome shows a
preference for aliphatic and charged amino acids in positions P1, P2, and P5 (Figure 8E). The cleavage
preference in position P1 is in line with the use of the chymotryptic-like CP active site. This specificity
is different from the previously described stimulation of tryptic and post-glutamyl cleavage activity
by PA200 [34,64] and is probably due to the use of N-Htt fragments in our study versus the use of
peptides [34] or chromatin extracts [64]. The N-Htt fragments have a specific amino acid composition
which will bias the use of the cleavage site.
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Next, we probed our peptide data for specific digestion patterns. Therefore, we analyzed first
the differences between the identified peptides from the in vitro degradation assays. The peptides
generated by the CP have a large overlap (71%) with the peptides produced by the CP-Blm10 complex
(Figure 8A). The amounts of the peptides were significantly higher in the CP-Blm10 experiment
(Figure 8B) indicating a higher throughput of the CP-Blm10 complex compared to the CP alone. To
look deeper into changes in the amino acid sequences of the generated peptides, we analyzed the
peptide sequences upstream of the cleavage sites of the identified peptides. To describe cleavage
specificity, we used the Berger and Schechter nomenclature [61]. Proteolytic cleavage depends on
substrate recognition by the protease [62,63]. According to Berger and Schechter, substrate residues
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specificity is different from the previously described stimulation of tryptic and post-glutamyl
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Figure 8. Characterization of the CP and CP BLM10 generated Htt peptides. (A) Venn diagram showing
Figure
8. Characterization
of the CP
andinCP
BLM10
generated Htt
peptides. A(A)
Venn
diagram
the overlap
of peptides identified
in the
vitro
Htt degradation
experiment.
total
of 71%
of the
showing
the
overlap
of
peptides
identified
in
the
in
vitro
Htt
degradation
experiment.
A
total
of 71%
identified peptides are shared between CP and Blm10-CP based degradation. (B) Blm10-CP
has a
higher processivity for the generation of peptides. More peptides were generated at the same time from
the Blm10-CP complex. (C) Scheme of the cleavage description. (D) Sequence logos of the peptides
generated by the CP and Blm10-CP complex. (E) Amino acid frequencies for hydrophobic and polar
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4. Discussion
S. cerevisiae (budding yeast) has been extensively used as a valid model of protein misfolding
diseases, including the neurodegenerative HD [55,65]. The advantages of studying yeast HD models
include but are not limited to the following. (1) No Htt ortholog exists in yeast. Thus, the resulting
phenotype, after introducing the recombinant Htt fragments in yeast, results in phenotypes independent
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of wild-type function. (2) Many effects of HD, such as cellular toxicity, mitochondrial dysfunction,
and proteolysis, can be observed and recapitulated in a yeast model, suggesting conserved functions [43,47,54].
The role of the proteasome in the degradation of huntingtin protein is an extensively studied
field. Altering or improving the activity of the proteasome by activators might offer a possible strategy
to accelerate the degradation of polyQ sequences and decrease the formation of toxic aggregates.
To investigate whether the degradation of N-Htt might be Blm10/PA200-dependent, we used a yeast
model and validated the results in a human neuroblastoma cell line. To study cytotoxicity in yeast,
we used a model developed by Meriin et al. [43]. The authors inserted the first 17 amino acids of
the HTT exon-1 followed by 25 or 103 glutamines into a pYES2-vector with a galactose-inducible
promoter (GAL1 promoter). Concomitant with their published data, we showed that Htt103Q not only
accumulates but also damages yeast cells.
Recently, we established that loss of BLM10 resulted in reduced viability when cells were exposed
to stress stimuli, such as acetic acid [31]. Using the inducible HD model, we studied the effects of
BLM10 loss on cellular toxicity and aggregate formation by different approaches. Our serial dilution
data demonstrate that the expression of the toxic Htt103Q aggravated cellular toxicity in the blm10∆
strains. Interestingly, deletion of the proteasome-related transcription factor Rpn4 did not result in
the same phenotype. That suggests that Blm10 might have a specific role in fighting against toxic Htt
and that blm10∆ cells might reach the N-Htt solubility threshold earlier, leading to elevated toxicity.
Furthermore, we also detected a significant increase in the number of large aggregates in the BLM10
deletion strain compared to WT and rpn4∆ by confocal microscopy. We propose that the impaired
degradation of N-Htt via Blm10-proteasomes enhances the formation and accumulation of toxic Htt103
aggregates and, thus, the cellular toxicity in blm10∆ cells.
In this study, we demonstrated that the proteasome activator Blm10/PA200 family contributes to
the degradation of soluble, nonaggregated wt and mutant N-Htt in vitro. Our in vitro degradation
assay indicates that both 20S CP and Blm10-CP degrade wt and toxic non-ubiquitinated N-Htt. Our
results are consistent with a previously published study showing that soluble N-Htt does not inhibit
20S CP proteasomes in vitro and that the addition of CP to the reaction generates a significant number
of peptides from the poly-Q stretch of Q18 and Q51 Htt [23,42,66]. To test the possibility that the
proteasome activator Blm10/PA200 family might be involved in the degradation of N-Htt in vitro, we
established a proteasome activity assay. We purified both 20S CP and Blm10 and purified GST-Htt18Q
and GST-Htt51Q. We did not cleave the GST by TEV protease, thus, we kept the GST-Htt18Q and
GST-Htt51Q in soluble forms. Our results demonstrate that the addition of purified Blm10 to the
20S CP preparation resulted in an acceleration of the degradation of non-ubiquitinated 18Q and 51Q
N-Htt in vitro. Moreover, our proteomics data demonstrate that the proteasome is not clogged by the
expanded polyQ repeats, but actively cleaves within polyQ stretches, and this ability is enhanced by
the addition of Blm10. Thus, we propose that the Blm10/PA200 proteasome activator family targets
soluble, non-ubiquitinated N-Htt polyQ repeats to proteasomal degradation and might help to delay
toxic aggregate formation and might help to reach solubility threshold later in cells (Figure 9).
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we demonstrated, by pull-down assays that endogenous PA200 binds to the soluble nontoxic wt and
soluble nonaggregated mutant N-Htt. However, we did not detect interaction between the catalytically
active β1 subunit of 20S CP and N-Htt by our pull-down assay. This might be explained by the fact
that the substrate gate is formed by the N-termini of the α-subunits, which also blocks unregulated
access to the catalytic sites [67]. In addition to the results observed in yeast, we detected significantly
larger aggregate size and a higher number of aggregates in human cells stably depleted of PA200. Very
interestingly, PA200 is also present in mHtt aggregates, suggesting that PA200 might be recruited and
accumulate in the SDS-insoluble aggregates of mHtt.
Although most of the published literature describes the mHtt aggregates as decorated by ubiquitin
and that soluble mHtt is polyubiquitinated in cells transfected with mHtt, others showed that
mHtt inclusion bodies (IBs) are lacking ubiquitin and that the soluble mHtt is not ubiquitinated
much [23,68,69]. Here, we also describe the ubiquitin-independent degradation of soluble N-Htt
fragments in vitro regulated by the Blm10/PA200 proteasomes. We speculate that the soluble wt and
mutant N-Htt polyQ peptides can be degraded by the 20S CP via a ubiquitin-independent pathway. This
ubiquitin-independent degradation is improved by the Blm10/PA200 activator family. The Blm10/PA200
family does not recognize ubiquitinated, globular proteins and does not participate in ATP-dependent
protein degradation, but they facilitate the degradation of short peptides [29,70]. Blm10 increases
the caspase-like and trypsin-like activity of the 20S CP and the recombinant PA200 increases the
tryptic-like and chymotryptic-like activity of the 20S CP [29,34]. Furthermore, adding endogenous
PA200 from bovine testis to purified 20S CP increases the caspase-like activity of the 20S CP and the
Blm10/PA200 activator family participates in the degradation of highly unstructured protein substrates,
such as tau [26,29]. In Htt, the first 17 N-terminal amino acids followed by the adjacent polyQ
are predominantly highly disordered in solution [71,72]; thus, it is tempting to speculate that these
highly disordered regions containing peptides are also substrates for the Blm10/PA200-proteasomes.
The proteasome species exist in the cell as mixed populations. Blm10/PA200-proteasomes, for example,
also exist as hybrid complexes, which can include the 19S and 20S CP, or the 20S CP as singly or
doubly capped complexes, such as in the mammalian testes for PA200 and in yeast for Blm10 [30,73].
In the cellular context, the ubiquitinated Htt is recognized, unfolded, and targeted to degradation
by the 26S. However, parallel to the ubiquitin-mediated pathway, the proteasome is opened up for
enhanced degradation to remove mostly unfolded proteins, including Htt with higher efficiency.
Thus, soluble, non-ubiquitinated polyQ monomers and oligomers might also be degraded by the
Blm10/PA200-proteasome complexes. Our data serve to further elucidate the Blm10/PA200-proteasome
complexes and identify new substrates. The specificities of the regulation are the subject of additional
studies. Furthermore, our results highlight the value of enhancing the activity of the proteasome by
proteasome activators, which may reduce toxic Htt accumulation and attenuate cellular toxicity in HD.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/11/1581/s1,
Figure S1: Representative merged immunofluorescence confocal images showing the cellular distribution of
PA200, Figure S2: Validation of PA200 depletion and the anti-PA200 antibody, Figure S3: PA200 binds to wt and
mutant N-Htt in vitro, Figure S4: Validation of normal and toxic N-Htt overexpression in control and shPA200
cells, Figure S5: The GST is not degraded by the proteasome complexes.
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